Migraine Drugs Flashcards
the signals created by the migraine generator are carried by the _________ system
- trigeminovascular
signals from the migraine generator induce the release of ______ from trigeminal sensory neurons in the dura mater and subarachnoid space
- calcitonin gene related peptide (CGRP)
CGRP binds to its cognate receptor on vascular smooth muscle and causes __________
may also induce
- vasodilation
- inflammatory response
- sensitization of trigeminal sensory neurons
data also show that the level of ______ in the brain decreases during migraines
role of this hormone
- serotonin
- induces vasoconstriction through 5HT-2A receptor
- blocks release of CGPR by agonizing the presynaptic 5HT-1B/D receptors on vascular smooth muscle
stimulation of beta 2 receptors on vascular smooth muscle causes
MOA of beta blockers
- relaxation
- vasodilation
- promote vasoconstriction
- reduce cranial blood flow
best beta blockers to use for preventing migraines
- propranolol
toxicities of beta blockers
- arrhythmias
- hypotension
examples of calcium channel blockers
- verapamil
MOA of calcium channel blockers in preventing migraine
- inhibit vascular smooth muscle contraction (which is weird because vasodilation is the problem normally)
- reduce BP
MOA of tricyclic SNRI anti-depressants in treating migraine
- increase synaptic concentrations of serotonin and NE
- promote serotonin-induced vasoconstriction in cranial arteries
- reduce likelihood that stress acts as a trigger for migraine attack
example of tricyclic SNRI used to treat migraines
- amitriptyline
toxicities of tricyclic SNRIs
what population do we not use these in?
- anti-cholinergic
- xerostoma, constipation, urinary retention, blurred vision
- not recommended in the elderly
the anti-seizure drugs ____ and ____ are first-line drugs in the prevention of migraines
MOA
- valproate
- topiramate
- may influence signaling pathways associated with the migraine generator
MOA of Erenumab
how often do you have to administer
- binds to CGRP receptor and prevents CGRP from activating it
- 4-12 weeks
MOA of Fremanezumab
how often do you have to administer
- binds CGRP itself and blocks binding to receptor
- 4-12 weeks